Tag: TCAR

Early Evaluation of Transcarotid Artery Revascularization (TCAR) Versus Carotid Endarterectomy (CEA) Cost-Effectiveness

Rosemont, Ill., Dec. 27, 2021 (GLOBE NEWSWIRE) — A cost-effectiveness model based on peer-reviewed sources suggests that although five-year costs for transcarotid artery revascularization (TCAR) were higher than those for carotid endarterectomy (CEA), TCAR afforded greater quality-adjusted life years (QALY). […]

First Ever Standard Surgical Risk Patient TCAR Data to be Presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting

SUNNYVALE, Calif., July 06, 2021 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that key data regarding standard risk patients undergoing treatment for atherosclerotic carotid […]

Results Demonstrating Favorable Outcomes with TCAR vs. TF-CAS in Patients with Carotid Artery Stenosis Published in the Journal of the American Medical Association (JAMA)

SUNNYVALE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that positive results from the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project comparing TCAR and […]

Silk Road Medical Announces Presentation of TCAR Data Demonstrating Favorable Outcomes in Patients with Carotid Artery Disease

SUNNYVALE, Calif.–(BUSINESS WIRE)–Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at […]